Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III PK, efficacy and safety study of rVIII-SingleChain in pediatric severe hemophilia A
2012-001336-65Phase 3Terminated
- Sponsor
- CSL Limited
- Start
- Oct 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lonoctocog alfa in hemophilia A, sponsored by CSL Limited. Primary endpoint: Treatment success. Started Oct 2013; status: terminated.
02
Drugs
lonoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2012-001336-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001336-65.